Lundbeck
39.2 DKK +1.55%2 investors are following this company
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Revenue
19.91B
EBIT %
16.05 %
P/E
16.97
Dividend yield-%
1.79 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
HLUN B
Daily low / high price
38.54 / 39.2
DKK
Market cap
39.03B DKK
Turnover
21.16M DKK
Volume
542K
Financial calendar
Interim report
21.08.2024
Interim report
13.11.2024
ShowingAll content types
H. Lundbeck A/S: Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial
H. Lundbeck A/S: Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools